Literature DB >> 19667187

R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice.

Youren Tong1, Antonio Pisani, Giuseppina Martella, Maha Karouani, Hiroo Yamaguchi, Emmanuel N Pothos, Jie Shen.   

Abstract

Dominantly inherited mutations in leucine-rich repeat kinase 2 (LRRK2) are a common genetic cause of Parkinson's disease (PD). The importance of the R1441 residue in the pathogenesis is highlighted by the identification of three distinct missense mutations. To investigate the pathogenic mechanism underlying LRRK2 dysfunction, we generated a knockin (KI) mouse in which the R1441C mutation is expressed under the control of the endogenous regulatory elements. Homozygous R1441C KI mice appear grossly normal and exhibit no dopaminergic (DA) neurodegeneration or alterations in steady-state levels of striatal dopamine up to 2 years of age. However, these KI mice show reductions in amphetamine (AMPH)-induced locomotor activity and stimulated catecholamine release in cultured chromaffin cells. The introduction of the R1441C mutation also impairs dopamine D2 receptor function, as suggested by decreased responses of KI mice in locomotor activity to the inhibitory effect of a D2 receptor agonist, quinpirole. Furthermore, the firing of nigral neurons in R1441C KI mice show reduced sensitivity to suppression induced by quinpirole, dopamine, or AMPH. Together, our data suggest that the R1441C mutation in LRRK2 impairs stimulated dopamine neurotransmission and D2 receptor function, which may represent pathogenic precursors preceding dopaminergic degeneration in PD brains.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19667187      PMCID: PMC2732807          DOI: 10.1073/pnas.0906334106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

1.  Dopamine D2 receptor-mediated inhibition of dopaminergic neurons in mice lacking D2L receptors.

Authors:  Diego Centonze; Alessandro Usiello; Paolo Gubellini; Antonio Pisani; Emiliana Borrelli; Giorgio Bernardi; Paolo Calabresi
Journal:  Neuropsychopharmacology       Date:  2002-11       Impact factor: 7.853

2.  An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family.

Authors:  Manabu Funayama; Kazuko Hasegawa; Etsuro Ohta; Noriko Kawashima; Masaru Komiyama; Hisayuki Kowa; Shoji Tsuji; Fumiya Obata
Journal:  Ann Neurol       Date:  2005-06       Impact factor: 10.422

Review 3.  Neuropathology of Parkinson's disease.

Authors:  L S Forno
Journal:  J Neuropathol Exp Neurol       Date:  1996-03       Impact factor: 3.685

Review 4.  LRRK2: a common pathway for parkinsonism, pathogenesis and prevention?

Authors:  Julie P Taylor; Ignacio F Mata; Matt J Farrer
Journal:  Trends Mol Med       Date:  2006-01-10       Impact factor: 11.951

5.  Localization of LRRK2 to membranous and vesicular structures in mammalian brain.

Authors:  Saskia Biskup; Darren J Moore; Fulvio Celsi; Shinji Higashi; Andrew B West; Shaida A Andrabi; Kaisa Kurkinen; Seong-Woon Yu; Joseph M Savitt; Henry J Waldvogel; Richard L M Faull; Piers C Emson; Reidun Torp; Ole P Ottersen; Ted M Dawson; Valina L Dawson
Journal:  Ann Neurol       Date:  2006-11       Impact factor: 10.422

6.  Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.

Authors:  Alan L Whone; Ray L Watts; A Jon Stoessl; Margaret Davis; Sven Reske; Claude Nahmias; Anthony E Lang; Olivier Rascol; Maria J Ribeiro; Philippe Remy; Werner H Poewe; Robert A Hauser; David J Brooks
Journal:  Ann Neurol       Date:  2003-07       Impact factor: 10.422

7.  Stimulation-dependent regulation of the pH, volume and quantal size of bovine and rodent secretory vesicles.

Authors:  Emmanuel N Pothos; Eugene Mosharov; Kuo-Peing Liu; Wanda Setlik; Marian Haburcak; Giulia Baldini; Michael D Gershon; Hadassah Tamir; David Sulzer
Journal:  J Physiol       Date:  2002-07-15       Impact factor: 5.182

Review 8.  Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease.

Authors:  Peter Jenner
Journal:  Curr Opin Neurol       Date:  2003-12       Impact factor: 5.710

Review 9.  A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters.

Authors:  S D Robertson; H J G Matthies; A Galli
Journal:  Mol Neurobiol       Date:  2009-02-06       Impact factor: 5.590

10.  Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.

Authors:  Alexander Zimprich; Saskia Biskup; Petra Leitner; Peter Lichtner; Matthew Farrer; Sarah Lincoln; Jennifer Kachergus; Mary Hulihan; Ryan J Uitti; Donald B Calne; A Jon Stoessl; Ronald F Pfeiffer; Nadja Patenge; Iria Carballo Carbajal; Peter Vieregge; Friedrich Asmus; Bertram Müller-Myhsok; Dennis W Dickson; Thomas Meitinger; Tim M Strom; Zbigniew K Wszolek; Thomas Gasser
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

View more
  141 in total

1.  Parkinson's disease: a model dilemma.

Authors:  M Flint Beal
Journal:  Nature       Date:  2010-08-26       Impact factor: 49.962

Review 2.  Parkinson's disease: insights from pathways.

Authors:  Mark R Cookson; Oliver Bandmann
Journal:  Hum Mol Genet       Date:  2010-04-26       Impact factor: 6.150

3.  Quantitative assessment of specificity in immunoelectron microscopy.

Authors:  John Milton Lucocq; Christian Gawden-Bone
Journal:  J Histochem Cytochem       Date:  2010-05-10       Impact factor: 2.479

Review 4.  Genetically engineered mouse models of Parkinson's disease.

Authors:  Donna M Crabtree; Jianhua Zhang
Journal:  Brain Res Bull       Date:  2011-08-03       Impact factor: 4.077

5.  Association between Parkinson's disease and G2019S and R1441C mutations of the LRRK2 gene.

Authors:  Xiao-Xia Li; Qin Liao; Huan Xia; Xin-Ling Yang
Journal:  Exp Ther Med       Date:  2015-07-27       Impact factor: 2.447

6.  Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.

Authors:  M Yue; K M Hinkle; P Davies; E Trushina; F C Fiesel; T A Christenson; A S Schroeder; L Zhang; E Bowles; B Behrouz; S J Lincoln; J E Beevers; A J Milnerwood; A Kurti; P J McLean; J D Fryer; W Springer; D W Dickson; M J Farrer; H L Melrose
Journal:  Neurobiol Dis       Date:  2015-03-31       Impact factor: 5.996

Review 7.  Role of LRRK2 kinase dysfunction in Parkinson disease.

Authors:  Azad Kumar; Mark R Cookson
Journal:  Expert Rev Mol Med       Date:  2011-06-13       Impact factor: 5.600

8.  LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity.

Authors:  Loukia Parisiadou; Jia Yu; Carmelo Sgobio; Chengsong Xie; Guoxiang Liu; Lixin Sun; Xing-Long Gu; Xian Lin; Nicole A Crowley; David M Lovinger; Huaibin Cai
Journal:  Nat Neurosci       Date:  2014-01-26       Impact factor: 24.884

9.  GTPase activity plays a key role in the pathobiology of LRRK2.

Authors:  Yulan Xiong; Candice E Coombes; Austin Kilaru; Xiaojie Li; Aaron D Gitler; William J Bowers; Valina L Dawson; Ted M Dawson; Darren J Moore
Journal:  PLoS Genet       Date:  2010-04-08       Impact factor: 5.917

10.  14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.

Authors:  R Jeremy Nichols; Nicolas Dzamko; Nicholas A Morrice; David G Campbell; Maria Deak; Alban Ordureau; Thomas Macartney; Youren Tong; Jie Shen; Alan R Prescott; Dario R Alessi
Journal:  Biochem J       Date:  2010-09-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.